Iconix Pharmaceuticals, Inc.

Entelos, Inc.

Stuart Tugendreich

Dongxu Sun

Edward Perkins

Georges Natsoulis

Michael Furness

Cecelia Pearson

Ving J Lee

Fernando Jose Rebelo Do Couto

The present invention includes methods and apparatus for use in rapid testing for and prediction of a PPAR&#x3b1; response (i.e. a response similar to that of PPAR&#x3b1; agonists). The invention includes a PPAR&#x3b1; response signature comprising a set of twenty genes. The invention discloses methods whereby the differential expression of the genes of the PPAR&#x3b1; response signature may be used to predict whether a compound will induce a PPAR&#x3b1; response in a test subject.

Peroxisome proliferation activated receptor alpha (PPAR&#x3b1;) signatures

The present invention provides methods and compositions for use in rapid test or prediction of the propensity of a test compound to induce cholesterol reduction in a subject. The invention also includes a cholesterol reduction signature as well as the method of deriving such signature.

Cholesterol reduction signature

The present invention provides methods and compositions for use in rapid test or prediction of the propensity of a test compound to induce cholestasis in a subject. The invention also includes a Cholestasis signature database as well as the method of deriving such database.

Cholestasis signature

Compounds of formula 1 modulate the activity of Rho C: 

Modulators of Rho C activity

Compounds of formula 1 modulate the activity of Rho C: wherein

A method for identifying a mutation-sensitive active region of a test protein, by providing a test nucleic acid construct comprising a regulatable promoter polynucleotide and a fusion polynucleotide comprising a test polynucleotide encoding the test protein fused to a reporter gene, wherein said fusion polynucleotide is operably associated with the promoter polynucleotide, wherein expression of the fusion polynucleotide in a selected host cell results in a specific phenotype and the presence of the reporter; mutagenizing the test nucleic acid construct to provide a mutagenized construct; transforming a selected host cell with the mutagenized construct to provide a transformed host cell; selecting a transformed host cell that exhibits the reporter, but which does not exhibit the specific phenotype; and sequencing a portion of the mutagenized construct from the selected transformed host cell to determine the alteration of the polynucleotide(s). The sequenced polynucleotides will exhibit alterations in one or more critical regions.

Growing community of inventors

Mountain View, CA, United States of America

Stuart Tugendreich